Systemic treatment of metastatic breast cancer: SABCS 2018

被引：0
作者：
Theresa Westphal
Simon Peter Gampenrieder
Richard Greil
机构：
[1] Paracelsus Medical University,Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute – Laboratory for Immunological and Molecular Cancer R
[2] Cancer Cluster,LIMCR)
来源：
memo - Magazine of European Medical Oncology | 2019年 / 12卷
关键词：
San Antonio Breast Cancer Symposium; Highlights; Review; IMpassion130; SOLAR-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
This review summarizes clinically relevant trials in metastatic breast cancer (MBC) presented at the 2018 San Antonio Breast Cancer Symposium (SABCS). At the meeting updates of two large phase III studies were presented: (1) the biomarker analysis of IMpassion130, trying to define the target population for the checkpoint inhibitor atezolizumab in triple-negative MBC and (2) a subgroup analysis of SOLAR-1, where the efficacy and safety of the alpha-specific Phosphoinositide 3(PI3)-kinase inhibitor alpelisib in combination with fulvestrant was investigated in patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−) MBC. Furthermore, we review the results of a randomized phase II trial (CCTG MA38) comparing a continuous daily dosing of palbociclib to the standard treatment dose, and the phase 1b data of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax in combination with tamoxifen as a novel drug combination in patients with HR+/HER2−MBC.
引用
收藏
页码：253 / 256
页数：3
相关论文
共 79 条
[1]  
Emens LALS(2019)Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer. Cancer Res Cancer Res 234 2693-2704
[2]  
Loi S(2019)Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer J Cell Physiol 14 173-3962
[3]  
Rugo HS(2016)Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies J Transl Med 79 GS3-08-34
[4]  
Schneeweiss A(2019)Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR-1 trial Cancer Res 69 3955-PD1
[5]  
Diéras V(2009)PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer Cancer Res 23 26-64
[6]  
Iwata H(2017)A phase Ib study of alpelisib (BYL719), a PI3Kalpha-specific inhibitor, with letrozole in ER+/HER2-metastatic breast cancer Clin Cancer Res 36 LBA1006-LBA-2771
[7]  
Abdollahpour-Alitappeh M(2018)Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER J Clin Oncol 366 520-1887
[8]  
Lotfinia M(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 79 PD1-06-129
[9]  
Bagheri N(2019)Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693) Cancer Res 20 54-undefined
[10]  
Sineh Sepehr K(2019)Abstract PD1-06: A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer (MBC) Cancer Res 109 2766-undefined
12345678